Our previous studies, and those of other laboratories, have documented the osteomimetic properties of Runx2 in primary tumors and that inhibition of Runx2 in breast and prostate cancer cells blocks metastasis and osteolytic bone disease mediated by human tumor cells in orthotopic mouse models [19, 21–23]. The gene discussed is RUNX2; the disease is neoplasm.